Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Long-acting injectable antipsychotics in first-episode schizophrenia.

Parellada E, Velligan DI, Emsley R, Kissling W.

Schizophr Res Treatment. 2012;2012:318535. doi: 10.1155/2012/318535. No abstract available.

2.

Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective.

Přikryl R, Přikrylová Kučerová H, Vrzalová M, Cešková E.

Schizophr Res Treatment. 2012;2012:764769. doi: 10.1155/2012/764769.

3.

Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.

Viala A, Cornic F, Vacheron MN.

Schizophr Res Treatment. 2012;2012:368687. doi: 10.1155/2012/368687.

4.
5.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
7.

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Int Clin Psychopharmacol. 2008 Nov;23(6):325-31. doi: 10.1097/YIC.0b013e32830c2042.

PMID:
18854720
8.
9.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
10.

Long-acting injectable antipsychotics. Review and recent developments.

Zolezzi M.

Neurosciences (Riyadh). 2005 Apr;10(2):126-31.

PMID:
22473224
11.

Risks versus benefits of different types of long-acting injectable antipsychotics.

McEvoy JP.

J Clin Psychiatry. 2006;67 Suppl 5:15-8. Review.

12.

Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A.

J Clin Psychiatry. 2012 Sep;73(9):1224-33. doi: 10.4088/JCP.11m06905.

PMID:
22938760
13.

Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.

Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S.

Eur Neuropsychopharmacol. 2007 Jan 15;17(2):138-44.

PMID:
17049818
14.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders..

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

15.
16.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
17.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group..

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
18.

[The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].

Faludi G.

Neuropsychopharmacol Hung. 2005 Mar;7(1):22-7. Review. Hungarian.

PMID:
16167464
19.
20.

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.

Bhanji NH, Chouinard G, Margolese HC.

Eur Neuropsychopharmacol. 2004 Mar;14(2):87-92. Review.

PMID:
15013023
Items per page

Supplemental Content

Support Center